SRF and hepatocellular carcinoma: Taken together, targeting MRTFs and SRF and its target genes such as MYOF represent promising therapeutic options for HCC by inducing cellular senescence and senescence-associated alterations in the cytoskeleton that cease HCC cell migration and proliferation.